Edwards Lifesciences Corporation $EW Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 0.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,083,292 shares of the medical research company’s stock after selling 6,759 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Edwards Lifesciences were worth $84,248,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its holdings in Edwards Lifesciences by 9.8% during the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after buying an additional 130 shares in the last quarter. Prosperity Consulting Group LLC raised its holdings in Edwards Lifesciences by 3.2% in the 2nd quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after purchasing an additional 132 shares during the period. Howard Capital Management Inc. raised its holdings in Edwards Lifesciences by 3.3% in the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after purchasing an additional 132 shares during the period. NewSquare Capital LLC boosted its position in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares in the last quarter. Finally, Empirical Finance LLC grew its holdings in Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock valued at $1,668,000 after purchasing an additional 134 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on EW shares. Wells Fargo & Company increased their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 target price (up previously from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Evercore reissued an “outperform” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Monday, January 5th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Finally, JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $90.00 to $100.00 in a research note on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Trading Down 0.8%

NYSE EW opened at $75.80 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The firm has a market cap of $43.99 billion, a price-to-earnings ratio of 41.42, a PEG ratio of 1.99 and a beta of 0.94. The firm has a 50 day simple moving average of $83.17 and a 200-day simple moving average of $81.06. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the company earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president directly owned 38,970 shares in the company, valued at $3,264,127.20. This represents a 22.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 43,804 shares of company stock worth $3,699,082. Company insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.